179 related articles for article (PubMed ID: 22034893)
1. The expression of c-Met pathway components in unclassified pleomorphic sarcoma/malignant fibrous histiocytoma (UPS/MFH): a tissue microarray study.
Lahat G; Zhang P; Zhu QS; Torres K; Ghadimi M; Smith KD; Wang WL; Lazar AJ; Lev D
Histopathology; 2011 Sep; 59(3):556-61. PubMed ID: 22034893
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma.
Roland CL; May CD; Watson KL; Al Sannaa GA; Dineen SP; Feig R; Landers S; Ingram DR; Wang WL; Guadagnolo BA; Feig B; Hunt KK; Cormier JN; Lazar AJ; Torres KE
Ann Surg Oncol; 2016 Jul; 23(7):2220-8. PubMed ID: 26847678
[TBL] [Abstract][Full Text] [Related]
3. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
[TBL] [Abstract][Full Text] [Related]
4. miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma.
Pazzaglia L; Novello C; Conti A; Pollino S; Picci P; Benassi MS
Cell Oncol (Dordr); 2017 Feb; 40(1):77-88. PubMed ID: 27900663
[TBL] [Abstract][Full Text] [Related]
5. Radiation-Associated Undifferentiated Pleomorphic Sarcoma is Associated with Worse Clinical Outcomes than Sporadic Lesions.
Dineen SP; Roland CL; Feig R; May C; Zhou S; Demicco E; Sannaa GA; Ingram D; Wang WL; Ravi V; Guadagnolo A; Lev D; Pollock RE; Hunt K; Cormier J; Lazar A; Feig B; Torres KE
Ann Surg Oncol; 2015 Nov; 22(12):3913-20. PubMed ID: 25743327
[TBL] [Abstract][Full Text] [Related]
6. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma.
Nakayama R; Nemoto T; Takahashi H; Ohta T; Kawai A; Seki K; Yoshida T; Toyama Y; Ichikawa H; Hasegawa T
Mod Pathol; 2007 Jul; 20(7):749-59. PubMed ID: 17464315
[TBL] [Abstract][Full Text] [Related]
7. Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors.
Fukuda T; Ichimura E; Shinozaki T; Sano T; Kashiwabara K; Oyama T; Nakajima T; Nakamura T
Pathol Int; 1998 Oct; 48(10):757-62. PubMed ID: 9788258
[TBL] [Abstract][Full Text] [Related]
8. Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma.
Mito JK; Riedel RF; Dodd L; Lahat G; Lazar AJ; Dodd RD; Stangenberg L; Eward WC; Hornicek FJ; Yoon SS; Brigman BE; Jacks T; Lev D; Mukherjee S; Kirsch DG
PLoS One; 2009 Nov; 4(11):e8075. PubMed ID: 19956606
[TBL] [Abstract][Full Text] [Related]
9. Predicting the prognosis of undifferentiated pleomorphic soft tissue sarcoma: a 20-year experience of 266 cases.
Vodanovich DA; Spelman T; May D; Slavin J; Choong PFM
ANZ J Surg; 2019 Sep; 89(9):1045-1050. PubMed ID: 31364245
[TBL] [Abstract][Full Text] [Related]
10. Undifferentiated pleomorphic sarcoma: Factors predictive of adverse outcomes.
Winchester D; Lehman J; Tello T; Chimato N; Hocker T; Kim S; Chang J; Markey J; Yom SS; Ryan W; Mully T; Hodge D; Otley C; Arron ST
J Am Acad Dermatol; 2018 Nov; 79(5):853-859. PubMed ID: 29787841
[TBL] [Abstract][Full Text] [Related]
11. Reassessment and clinicopathological prognostic factors of malignant fibrous histiocytoma of soft parts.
Oda Y; Tamiya S; Oshiro Y; Hachitanda Y; Kinukawa N; Iwamoto Y; Tsuneyoshi M
Pathol Int; 2002 Sep; 52(9):595-606. PubMed ID: 12406189
[TBL] [Abstract][Full Text] [Related]
12. Peritoneal sarcomatosis due to undifferentiated pleomorphic sarcoma: A case report and review of the literature.
Sogutcu N; Kavak S; Gumus S
Indian J Pathol Microbiol; 2023; 66(2):356-359. PubMed ID: 37077083
[TBL] [Abstract][Full Text] [Related]
13. Coexpression of hepatocyte growth factor and its receptor c-Met correlates with high MIB-1 proliferative index in malignant fibrous histiocytoma.
Yamamoto T; Marui T; Akisue T; Nakatani T; Fujita I; Matsumoto K; Hitora T; Kawamoto T; Nagira K; Kurosaka M
Pathol Res Pract; 2004; 200(5):397-402. PubMed ID: 15239348
[TBL] [Abstract][Full Text] [Related]
14. [Reassessment of the pathological diagnosis in 33 cases of malignant fibrous histiocytoma].
Guo H; Xiong Y; Nong L; Zhang S; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Aug; 40(4):374-9. PubMed ID: 18677383
[TBL] [Abstract][Full Text] [Related]
15. Characterization and signaling in a primary human malignant fibrous histiocytoma cell line.
Wang S; Bulsara S; Basson MD
J Invest Surg; 2010 Dec; 23(6):303-8. PubMed ID: 21208094
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of ezrin expression in pleomorphic malignant fibrous histiocytoma.
Kim MS; Cho WH; Song WS; Lee SY; Jeon DG
Anticancer Res; 2007; 27(2):1171-8. PubMed ID: 17465259
[TBL] [Abstract][Full Text] [Related]
17. Global protein-expression profiling for reclassification of malignant fibrous histiocytoma.
Kikuta K; Morioka H; Kawai A; Kondo T
Biochim Biophys Acta; 2015 Jun; 1854(6):696-701. PubMed ID: 25173742
[TBL] [Abstract][Full Text] [Related]
18. Primary malignant fibrous histiocytoma (myxofibrosarcoma/pleomorphic sarcoma not otherwise specified) of the breast: clinicopathologic study of 19 cases.
Hartel PH; Bratthauer G; Hartel JV; Fanburg-Smith JC
Ann Diagn Pathol; 2011 Dec; 15(6):407-13. PubMed ID: 21983422
[TBL] [Abstract][Full Text] [Related]
19. Atypical fibroxanthoma and malignant fibrous histiocytoma.
Withers AH; Brougham ND; Barber RM; Tan ST
J Plast Reconstr Aesthet Surg; 2011 Nov; 64(11):e273-8. PubMed ID: 21664889
[TBL] [Abstract][Full Text] [Related]
20. MFH and high-grade undifferentiated pleomorphic sarcoma-what's in a name?
Delisca GO; Mesko NW; Alamanda VK; Archer KR; Song Y; Halpern JL; Schwartz HS; Holt GE
J Surg Oncol; 2015 Feb; 111(2):173-7. PubMed ID: 25219789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
